Brief: Cti Biopharma Announces Topline Data From Final Analysis Of The Pre-Vent Clinical Trial Evaluating Pacritinib As A Treatment For Severe Covid-19

CTI Biopharma

01/10/2021 21:18

Oct 1 (Reuters) - CTI Biopharma Corp  CTIC.O :
    * CTI BIOPHARMA ANNOUNCES TOPLINE DATA FROM FINAL ANALYSIS
OF THE
PRE-VENT CLINICAL TRIAL EVALUATING PACRITINIB AS A TREATMENT FOR
SEVERE COVID-19
    * CTI BIOPHARMA CORP - PRE-VENT AMENDED TO A PHASE 2 STUDY
DUE TO
SHIFTING COVID-19 TREATMENT LANDSCAPE
    * CTI BIOPHARMA - PRE-VENT DID NOT ACHIEVE PRE-DEFINED
STATISTICAL
SIGNIFICANCE FOR PRIMARY ENDPOINT
    * CTI BIOPHARMA CORP - HAVE DECIDED NOT TO PURSUE FURTHER
DEVELOPMENT OF PACRITINIB FOR TREATMENT OF SEVERE COVID-19
    * CTI BIOPHARMA  - WILL CONTINUE TO FOCUS EFFORTS ON LAUNCH
PREPAREDNESS FOR PACRITINIB IN MYELOFIBROSIS

Source text for Eikon:  ID:nPn8kr7Gqa 
Further company coverage:  CTIC.O 

 ((Reuters.Briefs@thomsonreuters.com;))